Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 10/20 | 0.54 |
| ▸ | NPY1R | P25929 | 5/20 | 0.54 |
| ▸ | NPY2R | P49146 | 4/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 4/20 | 0.53 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.53 |
| ▸ | TFPI | P10646 | 1/20 | 0.52 |
| ▸ | GLP1R | P43220 | 1/20 | 0.51 |
| ▸ | SCTR | P47872 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.51 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.49 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30592739 | 0.96 | C5AR1 (0.55) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| SCHEMBL29641047 | 0.92 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| SCHEMBL29904555 | 0.90 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| SCHEMBL31064947 | 0.89 | BACE1 (0.55) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL30059086 | 0.88 | GLP1R (0.51) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL30309224 | 0.88 | C5AR1 (0.66) | NPY2RIL23RC5AR1GLP1R | |
| SCHEMBL30589457 | 0.88 | C5AR1 (0.45) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL29904562 | 0.87 | C5AR1 (0.55) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL30331172 | 0.87 | IL23R (0.51) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| SCHEMBL30974032 | 0.87 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5RC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711005-A2 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | Stealth BioTherapeutics Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TUFTS MEDICAL CENTER, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250263433-A1 | METHODS FOR REDUCING CD36 EXPRESSION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250255929-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-08-14 | — | — | US | disclosed |
| EP-4596049-A2 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12337023-B2 | Methods and compositions for the prevention and treatment of disease | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4302829-B1 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3603658-B1 | PEPTIDE FOR USE IN THE TREATMENT OF HEART FAILURE RESULTING FROM HYPERTROPHIC CARDIOMYOPATHY | UNIV CORNELL (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12102659-B2 | Methods for the prevention or treatment of heart failure | CORNELL UNIVERSITY (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4233887-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230149501-A1 | METHODS FOR REDUCING OXIDATIVE DAMAGE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-04-06 | — | — | US | disclosed |
| US-20230043587-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASE | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-3513800-B1 | AROMATIC-CATIONIC PEPTIDE FOR USE IN THE TREATMENT OF ANTIPHOSPHOLIPID SYNDROME | UNIV CORNELL (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4085920-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11376304-B2 | Methods and compositions for the prevention and treatment of disease | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11366104-B2 | Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-06-21 | — | — | US | disclosed |
| EP-4005582-A1 | TREATMENT OF LEFT VENTRICULAR REMODELING | Stealth BioTherapeutics Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4000690-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | Stealth BioTherapeutics Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043587-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASE | COL2A1, ALPI, COL14A1 | NPY4R 223/4885NPY1R 735/4885NPY2R 820/4885 |
| US-20250255929-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | TNNI3, TNNT2, FABP3 | NPY4R 2454/4885NPY1R 1553/4885NPY2R 2489/4885 |
| US-12337023-B2 | Methods and compositions for the prevention and treatment of disease | COL2A1, ALPI, COL14A1 | NPY4R 223/4885NPY1R 735/4885NPY2R 820/4885 |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | NPY4R 2905/4885NPY1R 2251/4885NPY2R 2584/4885 |
| US-12102659-B2 | Methods for the prevention or treatment of heart failure | TNNI3, FABP3, TNNC1 | NPY4R 881/4885NPY1R 807/4885NPY2R 696/4885 |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | NPY4R 2905/4885NPY1R 2251/4885NPY2R 2584/4885 |
| US-11376304-B2 | Methods and compositions for the prevention and treatment of disease | COL2A1, ALPI, COL14A1 | NPY4R 223/4885NPY1R 735/4885NPY2R 820/4885 |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TNNI3, TNNT2, MB | NPY4R 4783/4885NPY1R 4818/4885NPY2R 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.